# A Post-marketing Study to Monitor the Safety of a MF59-adjuvanted Influenza Vaccine Administered in Korean Subjects Aged 65 Years or Older

> **NCT01222403** · PHASE4 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 767 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Fluad_MF59-adjuvanted trivalent influenza subunit vaccine
- **BIOLOGICAL:** Vantaflu_MF59-adjuvanted trivalent influenza subunit vaccine

## Key facts

- **NCT ID:** NCT01222403
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 767 (ACTUAL)
- **Last updated:** 2019-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01222403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01222403, "A Post-marketing Study to Monitor the Safety of a MF59-adjuvanted Influenza Vaccine Administered in Korean Subjects Aged 65 Years or Older". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01222403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*